Gary Blick MD

Internal Medicine•Stratford, CT

HIV/AIDS Medicine, Preventive Medicine, STD Medicine

Chief Medical Officer, Health Care Advocates International

Join to View Full Profile

2595 Main StStratford, CT 06615
Phone+1 203-345-0404
Fax+1 203-908-4110

Education & Training

Yale-New Haven Medical CenterResidency, Internal Medicine, 1985 - 1987
University of Miami/Jackson Health SystemInternship, Internal Medicine, 1984 - 1985
University of Miami Leonard M. Miller School of MedicineClass of 1984

Certifications & Licensure

RI State Medical License 2024 - 2026
CT State Medical License 1986 - 2025
NY State Medical License 1985 - 2025
American Academy of HIV MedicineHIV SPECIALIST

Clinical Trials

Safety and Effectiveness of Combining Hydroxyurea (HU) With Didanosine (ddI) and Stavudine (d4T) for Treatment of HIV-Infected Adults Start of enrollment: 1999 May 01
Completed
Phase 1
A Comparison of Emtricitabine and Stavudine Used With Didanosine Plus Efavirenz in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs Start of enrollment: 2000 Aug 01
Unknown status
Phase 3
A Rollover Study for Subjects Who Completed Participation in the VRX496-USA-05-002 Trial Start of enrollment: 2007 Dec 01
Active, not recruiting
Phase 2
Safety and Efficacy Study of Switching From Epzicom to Truvada Start of enrollment: 2008 Jul 01
Completed
Phase 4
Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Start of enrollment: 2010 Nov 01
Completed
Phase 1, Phase 2
Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T Start of enrollment: 2011 Dec 01
Completed
Phase 1, Phase 2
Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir Start of enrollment: 2012 Apr 18
Completed
Phase 3
Long-term Observational Study in HIV Subjects Exposed to EGRIFTA® Start of enrollment: 2013 Feb 01
Terminated
Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART Start of enrollment: 2014 Aug 01
Completed
Phase 1, Phase 2
Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018) Start of enrollment: 2014 Dec 01
COMPLETED
PHASE3
Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients Start of enrollment: 2016 Mar 10
ACTIVE_NOT_RECRUITING
PHASE1
Join now to see all

Publications & Presentations

PubMed

1 citations
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study.
Stefan Schneider, Gary Blick, Christina Burke, Douglas Ward, Paul Benson
Infectious Diseases and Therapy. 2024-04-01
9 citations
Virologic Response to Dolutegravir Plus Lamivudine in People With Suppressed Human Immunodeficiency Virus Type 1 and Historical M184V/I: A Systematic Literature Review...
Madhusudan Kabra, Tristan J Barber, Clotilde Allavena, Anne-Geneviève Marcelin, Simona Di Giambenedetto
Open Forum Infectious Diseases. 2023-11-01
19 citations
Exploring Social Networking Technologies as Tools for HIV Prevention for Men Who Have Sex With Men.
Jorge Ramallo, Thomas Kidder, Tashuna Albritton, Gary Blick, John E. Pachankis
AIDS Education and Prevention. 2015-08-01

Press Mentions

COVID-19 Increases Urgency for Legislature to Pass Medical Aid-in-Dying LawFebruary 26th, 2021
Front Line Hero of COVID-19 Crisis, LGBTQ Advocate HonoredAugust 30th, 2020
Renown HIV Specialist Dr. Gary Blick Joins Immune Therapeutics Advisory BoardAugust 23rd, 2018
Join now to see all

Professional Memberships

American Medical Association - AMA
Member
American Academy of HIV Medicine
Member
International AIDS Society
Member
HIV Medical Association
Member
International Association of Providers of AIDS Care
Member
CT State Medical Society
Member
Fairfield County Medical Association
Member